Christopher D'angelo, MD
Critical Care Medicine · Celebration, FLNPI 1982099776
Payments from drug & device makers
Across 248 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Getinge USA Sales, LLC$458
- Regeneron Healthcare Solutions, Inc.$303
- Boehringer Ingelheim$282
- Mallinckrodt Enterprises LLC$271
- plus $2K from 32 others
What the payments were for
- Travel & lodging$4588%
- Food & beverage$5,23192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $1,244 |
| AstraZeneca | 28 | $1,058 |
| Getinge USA Sales, LLC | 1 | $458 |
| Regeneron Healthcare Solutions, Inc. | 21 | $303 |
| Boehringer Ingelheim | 14 | $282 |
| Mallinckrodt Enterprises LLC | 4 | $271 |
| Mylan Specialty L.p. | 12 | $256 |
| Insmed, Inc. | 3 | $244 |
| Pulmonx Corporation | 1 | $137 |
| Actelion Pharmaceuticals US, Inc. | 2 | $135 |
| Amgen | 2 | $108 |
| Corcept Therapeutics | 4 | $91 |
| Lilly USA, LLC | 6 | $89 |
| Sanofi | 4 | $81 |
| Verona Pharma, Inc. | 3 | $78 |
| Viatris Specialty LLC | 3 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Novartis | 4 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| Lundbeck LLC | 3 | $61 |
| Optinose US, Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Abiomed | 2 | $55 |
| Johnson & Johnson | 3 | $53 |
| United Therapeutics Corporation | 2 | $32 |
| Merck | 2 | $31 |
| Novo Nordisk | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Pfizer | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| ERBE USA Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vasoview Hemopro 2$458
- FASENRA$369
- ACTHAR$243
- NUCALA$240
- CHARTIS CATHETER$137
- ZEPHYR DELIVERY CATHETER$137
- ZEPHYR ENDOBRONCHIAL VALVE$137
- PULMONX CHARTIS TABLET CONSOLE$137
- TEZSPIRE$119
How this compares
$5,689 in reported general payments places this provider in the 85th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 73 | $287,464 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 202 | $234,490 |
| Fasenra PenBenralizumab | 37 | $209,831 |
| NucalaMepolizumab | 28 | $107,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $54,982 |
| Advair HfaFluticasone Propion/Salmeterol | 62 | $50,206 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $23,678 |
| Spiriva HandihalerTiotropium Bromide | 13 | $9,639 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,001 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,368 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 45 | $7,391 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,235 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 179 | $7,173 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $4,794 |
| Fluticasone Propionate | 11 | $1,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $1,244 | $373,859283 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,058 | $62,21782 claims |
| Boehringer IngelheimSpiriva Respimat | $282 | $9,00117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Celebration
- Jeffrey LevyHollywood$19M
- Ahmad AswadMiami$6.6M
- George DuvallVero Beach$6M
- Fortune AlabiKissimmee$3.2M
- Carlos VacaMiami$3M
- Debabrata BandyopadhyayTampa$1.9M
- Christopher HardenGainesville$713K
- Fred UmehKissimmee$682K
- Ali AtayaGainesville$672K
- George AzarFt Lauderdale$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.